Precise Insights
Advanced Data and AI for Renal Cancer
On-demand access to the largest and most sophisticated oncology data for accelerated RWE and improved patient outcomes.
labs
Results from variety of patient tests
Visits
Oncology practice visits
Observations
Tumor-related observations plus vitals, biometrics, pain, and more
Procedures
Surgeries, radiation, biopsies, imaging, chemotherapy, etc.
Medications
Start and end dates, brand vs. generic codes, dosage, duration, and cycles
Diagnoses
Disease state, status, severity, and metastasis
Biomarkers
Biomarker testing, results, and timing
Disease Progression
Directly-observed measures of critical endpoints
Adverse Events
Different types of adverse responses
Histology
Classification into multiple categories
Cost & Utilization
Adjudicated costs with linked claims data
Safety, Comorbidities
Pre-cancer and claims charge events
Specialty Pharmacy & Hub
Rx acquisition status details
Payer & Formulary
Drug tiers and coverage
Social Determinants
Social and physical environment factors
Date of Metastasis
Rules-based imputation of date of metastasis
Metastatic Status
Imputation of missing data from unstructured notes
Date of Initial Dx
Imputation of index event
Line of Therapy
Regimen or progression-based drug classes
Patient Adherence
Identify root cause of product switching
Patient Acquisition
Predict factors driving patients’ brand decision
Results
633
Patients in registry
Findings:
Patients received sunitinib, sorafenib, temsirolimus, or pazopanib
The model improved accuracy:
Had ECOG >1
Compared to trial population
Registry patients:
Years older than clinical trial subjects
Failed to meet Phase III trial inclusion criteria